Plain-English translation of NCT06136728 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Sclerosis research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether dalfampridine—a medication that helps nerve signals travel better in the brain and spinal cord—works better when combined with hands-on physical therapy to improve walking. Many people with multiple sclerosis struggle with walking, and this study wants to see if using this medication alongside specialized physical therapy can help more than using either treatment by itself.
Walking problems affect most people with multiple sclerosis, and while this medication and physical therapy have both been shown to help separately, no one has studied what happens when you combine them. Researchers believe that this medication might actually help the brain learn and adapt better during physical therapy, making the benefits last longer.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of three groups: the medication alone, physical therapy alone, or both combined. If you get physical therapy, you'll come to the clinic twice a week for one-on-one sessions focused on improving your walking. If you get the medication, you'll take a tablet twice daily. The study will track your walking ability and use brain imaging to see how your brain is responding to the treatment.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
United States